Monoclonal Antibodies

At ACS Dobfar, innovation is a continuous journey. Today, that journey is taking us to a new frontier: the development of a state-of-the-art platform entirely dedicated to monoclonal antibodies (mAbs). 

As a focused CDMO, our mission is to partner with innovators to advance complex biologics from early development to clinical manufacturing.  We support our partners during the most critical stages of drug development — particularly Phase 1 and Phase 2 clinical programs — helping transform promising research into viable therapeutic solutions. 

We look toward 2028 with pride: our new 200-litre facility will become the beating heart of this revolution, where technological precision meets a passion for life. 

Innovation That Breathes: Biocatalysis and Our Commitment to the Planet 

At ACS Dobfar, science is never an end in itself — it is the tool with which we safeguard tomorrow. The purification and immobilization of enzymes represent the core of a silent revolution for us: the revolution of green chemistry. As outlined in our Sustainability objectives, the strategic use of biocatalysts is the keystone for lowering emissions and reducing the environmental footprint of every process. 

We share know-how, experience, and vision. We do not want to walk the path of sustainability alone. 

We are ready to make this expertise available to those who, like us, believe in ethical industrial production, offering a unique market solution for integration and flexibility. 

A Dynamic Sourcing Model: The Starting Point for Your Solution 

Our turnkey biocatalysis model is designed to adapt to the specific needs of each partner, ensuring efficiency and technological excellence from the earliest development stages. 

• Customer Engineering Enhancement: We are the ideal partner to industrialize and immobilize enzymes provided by our clients, bringing them to maximum production efficiency. 
• Enzymatic Evolution and Research: Through strategic collaborations with leading research centers and companies specializing in enzyme evolution, we identify and develop the perfect biocatalyst for your target molecule. 

The Uniqueness of an Integrated Supply Chain 

ACS Dobfar is among the few global organizations able to provide a fully integrated development and manufacturing platform, supporting pharmaceutical partners across the entire value chain. 

• Biocatalyst Identification and Optimization – Selection and development of the most effective enzyme systems. 
• API Development and Manufacturing – Production of active pharmaceutical ingredients using efficient and low-impact processes. 
• Finished Product Supply – From bulk production to packaged finished products ready for the market.

More than a service provider, ACS Dobfar acts as a strategic development and manufacturing partner, helping clients accelerate innovation, optimize processes, and bring new therapies to patients faster — while reducing environmental impact.